Skip to content

In Vivo and Clinical Study of Daruharidra Ghan Vati in Sthula Madhumeha that is Diabetes Mellitus

In Vivo and Randomized Control Trial of Daruharidradi Ghanavati in Sthula Madhumeha with specific reference to Type II Diabetes Mellitus

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/01/017270
Enrollment
200
Registered
2019-01-25
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Daruharidradi Ghanavati: ‘Daruharidradi Ghanavati 500 mg twice in a day before lunch and dinner with leukwarm water for three months ’ will be given to patients in Trial Group Control

Sponsors

SUSHIL VILAS CHAWRE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. The patients having fasting plasma sugar level more than or equal to 126mg/dl and post prandial plasma sugar level more than or equal to 200mg/dl (A.D.A 2016) 2. The patients fulfilling criteria of diagnosis and having clinical features of Sthula Madhumeha (Diabetes Mellitus) 3. Patients having BMI more than 23Kg/m2 up to 30Kg/m2 will be selected. 4. HbA1c is 6.5%up to 10%. 5. Patients having age between 30years to 70 years. 6. Those are willing to participate in trial and ready to give their written consent.

Exclusion criteria

Exclusion criteria: 1. Patients who already taking anti-diabetic drugs. 2. Patients with fasting plasma sugar level >250mg/dl and post meal plasma sugar level >350mg/dl. 3. Patients having insulin dependent diabetes mellitus and juvenile diabetes and various other types of diabetes except Type II DM. 4.Patients having BMI less than 23kg/m2 and More Than 30kg/m2. 5. HbA1c more than 10%. 6. Patients having age below 30 years and above 70 years. 7. Patients who are currently participating in any other clinical trials since last 6 months. 8. Patients having complications such as vasculopathy, nephropathy, retinopathy and neuropathy. 9. Patients having other systemic complications like hepatic, renal and cardiac problems. 10. Patients having poorly controlled blood pressure. 11. Pregnant and lactating females not included in this study.

Design outcomes

Primary

MeasureTime frame
1. To study the effect of Daruharidradi Ghanavati in Streptozotocin induced diabetes Mellitus in Wister rats specifically on blood sugar level. 2.To study the effect of Daruharidradi Ghanavati on Sthula Madhumeha with specific reference to type II diabetes mellitus, on fasting and post prandial plasma sugar level and HbA1c,and to compare its effect with metformin.Timepoint: 1.In Animal study-In Rats anti diabetic effect will be assessed after one month.. In Clinical trial - 1.On zero day i.e. before treatment value. 2.In trial group Daruharidradi Ghan Vati 500mg twice a day and in control group tablet Metformin 500mg twice a day will be given for 3months. 3.Follow up and assessment will be done on every 15days after starting medicine up to 90 days. 4.Final assessment will be done on ninety first day.

Secondary

MeasureTime frame
1. To study the toxic effects of Daruharidradi Ghanavati by investigating LFT, KFT and relevant histo-pathological investigations in Swiss Albino mice. 2. To study the literature of Madhumeha as per Ayurvedic perspective. 3. To study the literature of Diabetes Mellitus.Timepoint: 1.The oral chronic effect of Daruharidradi Ghan vati and Metformin in Swiss albino mice will be assess on ninety first day. 2. The assessment of all study will be evaluate after completion of study.

Countries

India

Contacts

Public ContactPRAKASH RAMNARAYAN KABRA

Government Ayurved College and Hospital, Sakkaradara Square, Raje Raghuji Nagar, Umred Road, Nagpur

kabraprakash2711@gmail.com9225226567

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026